Maldonado-Alcaraz E, Moreno-Palacios J, López- Sámano VA, Landa-Salas JD, Torres-Mercado LO, García-Cruza C

Language: Spanish
References: 24
Page: 568-574
PDF size: 477.00 Kb.

ABSTRACT

Background: The aim of this paper is to compare the efficacy of tamsulosin, oxybutynin or their combination for the treatment of symptoms related to double J stent (DJS).
Methods: Randomized clinical non-blinded trial with three arms (tamsulosin, oxybutynin or combination) to assess the improvement of ureteral related symptoms with DJS with the questionnaire of Ureteral Stent Symptom Questionnaire (USSQ) and the adverse effects of treatment. Evaluations were made at 7 and 21 days after the placement of DJS. The maneuvers were compared using Chi squared test, Kruskall-Wallis, ANOVA and Wilcoxon considering a statistically significant p ≤ 0.05.
Results: 170 patients with CJJ were evaluated. A perprotocol analysis was performed in 142 patients, 53 received tamsulosin (37.4%), 42 oxybutynin (29.6%) and 47 the combination of both (33%). At 7 and 21 days the improvement was similar in all three arms. Men with tamsulosin and women with oxybutynin had less general symptoms.
Conclusions: Tamsulosin, oxybutynin or its combination similarly improve ureteral stent related symptoms and this improvement becomes more noticeable over time. Men are less symptomatic with tamsulosin and women with oxybutynin.

REFERENCES

1. Zimskind PD, Fetter TR, Wilkerson JL. Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol. 1967;97(5):840-4.

2. Miyaoka R, Monga M. Ureteral stent discomfort: Etiology and management. Indian J Urol. 2009;25(4):455-60.

3. Chew BH, Knudsen BE, Denstedt JD. The use of stents in contemporary urology. Curr Opin Urol. 2004;14(2):111-5.

4. Knudsen BE, Beiko DT, Denstedt JD. Stenting after ureteroscopy: pros and cons. Urol Clin North Am. 2004;31(1):173-80.

5. Damiano R, Autorino R, De Sio M, Cantiello F, Quarto G, Perdona S et al. Does the size of ureteral stent impact urinary symptoms and quality of life? A prospective randomized study. Eur Urol. 2005;48(4):673-8.

6. Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr., Timoney AG, Barry MJ. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol. 2003;169(3):1065-9.

7. Thomas R. Indwelling ureteral stents: impact of material and shape on patient comfort. J Endourol. 1993;7(2):137-40.

8. Davenport K, Kumar V, Collins J, Melotti R, Timoney AG, Keeley FX Jr. New ureteral stent design does not improve patient quality of life: a randomized, controlled trial. J Urol. 2011;185(1):175-8.

9. Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr., Timoney AG. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol. 2003;169(3):1060-4.

10. Jirschele K, Sand PK. Oxybutynin: past, present, and future. Int Urogynecol J. 2013;24(4):595-604.

11. Lee SJ, Yoo C, Oh CY, Lee YS, Cho ST, Lee SH et al. Stent position is more important than alpha-blockers or anticholinergics for stent-related lower urinary tract symptoms after ureteroscopic ureterolithotomy: A prospective randomized study. Korean J Urol. 2010;51(9):636-41.

12. Kuyumcuoglu U, Eryildirim B, Tuncer M, Faydaci G, Tarhan F, Ozgul A. Effectiveness of medical treatment in overcoming the ureteral double-J stent related symptoms. Can Urol Assoc J. 2012;6(6):E234-7.

13. Park SC, Jung SW, Lee JW, Rim JS. The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. J Endourol. 2009;23(11):1913-7.

14. Beiko DT, Watterson JD, Knudsen BE, Nott L, Pautler SE, Brock GB et al. Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. J Endourol. 2004;18(8):723-30.

15. Norris RD, Sur RL, Springhart WP, Marguet CG, Mathias BJ, Pietrow PK et al. A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort. Urology. 2008;71(5):792-5.

16. Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM. Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology. 2006;67(1):35-9.

17. Choo MS, Lee JZ, Lee JB, Kim YH, Jung HC, Lee KS et al. Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study. Int J Clin Pract. 2008;62(11):1675-83.

18. Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D’Armiento M. Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol. 2008;22(4):651-6.

19. Wang CJ, Huang SW, Chang CH. Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol Res. 2009;37(3):147-52.

20. Lamb AD, Vowler SL, Johnston R, Dunn N, Wiseman OJ. Meta-analysis showing the beneficial effect of alpha-blockers on ureteric stent discomfort. BJU Int. 2011;108(11):1894-902.

21. Shalaby E, Ahmed AF, Maarouf A, Yahia I, Ali M, Ghobish A. Randomized controlled trial to compare the safety and efficacy of tamsulosin, solifenacin, and combination of both in treatment of double-j stent-related lower urinary symptoms. Adv Urol. 2013;2013:752382.

22. Yakoubi R, Lemdani M, Monga M, Villers A, Koenig P. Is there a role for alpha-blockers in ureteral stent related symptoms? A systematic review and metaanalysis. J Urol. 2011;186(3):928-34.

23. Türk C, Knoll T, Petrik A, Sarica K, Skolarikos A, Straub M, Seitz C. EAU Guidelines on Interventional Treatment for Urolithiasis. Eur Urol. 2016;69(3):475-82.

24. Assimos D, Krambeck A, Miller N, Monga M, Murad M, Nelson C, Pace K, Pais V, Pearle M, Preminger G, Razvi H, Shah O, Matlaga B. Surgical Management of Stones: American Urological Association/ Endourological Society Guideline, Part I-II. J Urol. 2016.